Payment overview · 2025
General Payments
$239.94
13 reported records · 6 companies
Healthcare provider profile · identity verified
Thomas Aaron Buice, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BARNESVILLE, GA · NPI 1194754648
Verified facts
What the public records show
CMS Open Payments records show Thomas Aaron Buice, M.D. received $239.94 in general payments during 2025 across 13 reported records.
Exact Sciences Corporation accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.43 | 29.8% | 4 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.61 | 25.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.99 | 21.2% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.85 | 9.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.59 | 7.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.47 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $239.94 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $60.61 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.11 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.99 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 293 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 224 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 202 | 52 |
| Lisinopril | Lisinopril | 155 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 50 |
| Metformin Hcl | Metformin Hcl | 150 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 35 |
| Gabapentin | Gabapentin | 105 | 34 |
| Omeprazole | Omeprazole | 104 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 92 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 26 |
| Montelukast Sodium | Montelukast Sodium | 89 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 27 |
| Losartan Potassium | Losartan Potassium | 74 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 18 |
| Simvastatin | Simvastatin | 58 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 16 |
| Alendronate Sodium | Alendronate Sodium | 48 | 17 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 12 |
| Potassium Chloride | Potassium Chloride | 44 | 17 |
| Carvedilol | Carvedilol | 43 | 13 |
| Sertraline Hcl | Sertraline Hcl | 43 | 15 |
| Famotidine | Famotidine | 42 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 18 |
| Eliquis | Apixaban | 39 | 11 |
| Ozempic | Semaglutide | 39 | suppressed |
| Furosemide | Furosemide | 38 | 17 |
| Metformin Hcl Er | Metformin Hcl | 38 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 16 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 24 |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 18 |
| Meloxicam | Meloxicam | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 17 |
| Trazodone Hcl | Trazodone Hcl | 21 | 11 |
| Buprenorphine Hcl | Buprenorphine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Nystatin | Nystatin | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Fentanyl | Fentanyl | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Baclofen | Baclofen | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $239.94 · 13 records | Exact Sciences Corporation | Cologuard Collection Kit, FANAPT, Korlym, MOUNJARO, NUZYRA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error